Get the Stockscreener App
22.11
3.88%
0.825
Nanobiotix Adr stock is traded at $22.11, with a volume of 53,160.
It is up +3.88% in the last 24 hours and down -37.31% over the past month.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
See More
Previous Close:
$21.28
Open:
$21.89
24h Volume:
53,160
Relative Volume:
0.32
Market Cap:
$1.13B
Revenue:
$32.72M
Net Income/Loss:
$-27.55M
P/E Ratio:
-38.66
EPS:
-0.5718
Net Cash Flow:
$-41.40M
1W Performance:
-3.47%
1M Performance:
-37.31%
6M Performance:
-33.42%
1Y Performance:
-20.46%
1-Day Range:
$21.55
$22.55
1-Week Range:
$21.14
$24.50
52-Week Range:
$14.78
$57.14
Nanobiotix Adr Stock (NBTX) Company Profile
Compare NBTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
22.11 | 1.13B | 32.72M | -27.55M | -41.40M | -0.5718 |
VRTX
Vertex Pharmaceuticals Inc
|
509.74 | 129.20B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.26 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.01 | 53.39B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-26 | Resumed | Guggenheim | Buy |
| Feb-06-26 | Initiated | TD Cowen | Buy |
| Aug-28-24 | Initiated | Guggenheim | Buy |
| Dec-08-23 | Initiated | Leerink Partners | Outperform |
| Jan-06-21 | Initiated | Evercore ISI | Outperform |
Nanobiotix Adr Stock (NBTX) Latest News
NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 7.71%Earnings Volatility Report - https://www.dars.gov.et/
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
NBTX Edges Lower: Nanobiotix Holds Near $33 as Traders Eye $31.64 SupportRelative Volume - https://www.siam.in/
NBTX Edges Lower: Nanobiotix Holds Near $33 as Traders Eye $31.64 SupportTriangle Correction - dars.gov.et
NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus EstimateAnnual Earnings Summary - www.dars.gov.et
NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus EstimatePre-Announcement Alert - www.dars.gov.et
NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus EstimateRevenue Miss Report - dars.gov.et
NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus EstimateAnnual Financial Report - dars.gov.et
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17%Buyback Announcement Report - dars.gov.et
NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17%Subscription Growth Report - careplusvn.com
NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17%Positive Surprise Momentum - www.dars.gov.et
Biophytis (BPTS) Peer Comparison – Compare with Others - valueresearchonline.com
Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30%Earnings Whisper Number - careplusvn.com
Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30%Growth Acceleration Report - dars.gov.et
Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30%Final Results - www.dars.gov.et
Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30%Healthcare Earnings Report - dars.gov.et
Nanobiotix (NBTX) Q4 2025 Filing Snapshot: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings Trading: The Stock Records a 3.23% DecreaseDownward Estimate Revision - dars.gov.et
Nanobiotix (NBTX) Q4 2025 Filing Snapshot: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings Trading: The Stock Records a 3.23% DecreaseFinancial Data - www.dars.gov.et
NBTX Q4 2025 Earnings: Clinical-Stage Burn and a Wide EPS MissROE Trend Analysis - careplusvn.com
NBTX Q4 2025 Earnings: Clinical-Stage Burn and a Wide EPS MissSubscription Growth Report - dars.gov.et
Nanobiotix (NASDAQ:NBTX) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Nanobiotix S.A. (NBTX) investor group reports 9.4% stake and pre-funded warrants - Stock Titan
Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws InterestForce Index - dars.gov.et
Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws InterestMedian Line - dars.gov.et
Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws InterestSwing Trade Setups - www.dars.gov.et
Nanobiotix (NASDAQ:NBTX) Shares Gap UpHere's What Happened - MarketBeat
Nanobiotix (NBTX) Q4 2025 Earnings: Missed EPS Estimate by Wide Margin as Stock SlipsConsensus Beat Rate - careplusvn.com
Nanobiotix S.A.Sponsored ADR (NASDAQ:NBTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Nanobiotix (NBTX) Q4 2025 Earnings: Missed EPS Estimate by Wide Margin as Stock SlipsMid-Term Outlook - dars.gov.et
Qatar Investment Authority (NBTX) reports 3.53M Nanobiotix ADRs under sole control - Stock Titan
Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.4%What's Next? - MarketBeat
Nanobiotix (NBTX) Faces Selling Pressure: Approaching Key Support After 4% DeclineVWAP Bounce - careplusvn.com
Nanobiotix (NBTX) Faces Selling Pressure: Approaching Key Support After 4% DeclineFRAMA Signal - dars.gov.et
SK hynix Inc. American Depositary Shares (SKHY) Historical Data - Nasdaq
NBTXNanobiotix ADR Dividends - Finviz
5NRA Forecast — Price Target — Prediction for 2027 - TradingView
5NRA Forecast — Price Target — Prediction for 2027 - TradingView
NBTX Stock Price, Quote & Chart - ChartMill
NBTXNanobiotix ADR Options - Finviz
NANOBIOTIX Announces Closing of Global Offering - GlobeNewswire Inc.
NBTX - Finviz
NANOBIOTIX Announces Closing of Global Offering - GlobeNewswire
NANOBIOTIX Announces Closing of Global Offering - Finansavisen
NANOBIOTIX Announces Closing of Global Offering - GlobeNewswire
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering - GlobeNewswire Inc.
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris - Yahoo Finance UK
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris - Barchart.com
Nanobiotix: Trading Halt on Euronext Paris for a Global Securities Offering - ideal-investisseur.fr
Nanobiotix Adr Stock (NBTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
2.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):